OTCMKTS:GOVX - Geovax Labs Stock Price, News & Analysis

$0.0115
0.00 (-10.16 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$0.0112
Now: $0.0115
$0.0142
50-Day Range
$0.01
MA: $0.05
$0.15
52-Week Range
$0.0112
Now: $0.0115
$16.00
Volume4.75 million shs
Average Volume275,796 shs
Market Capitalization$30,785.50
P/E RatioN/A
Dividend YieldN/A
Beta0.5
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GOVX
Previous SymbolNASDAQ:GOVX
CUSIPN/A
Phone678-384-7220

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$960,000.00
Book Value($6.84) per share

Profitability

Net Income$-2,560,000.00
Net Margins-217.43%

Miscellaneous

Employees8
Market Cap$30,785.50
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.


Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) issued its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.03. The biotechnology company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.30 million. View Geovax Labs' Earnings History.

When is Geovax Labs' next earnings date?

Geovax Labs is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Geovax Labs.

Has Geovax Labs been receiving favorable news coverage?

Media coverage about GOVX stock has trended negative on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Geovax Labs earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Geovax Labs.

Who are some of Geovax Labs' key competitors?

What other stocks do shareholders of Geovax Labs own?

Who are Geovax Labs' key executives?

Geovax Labs' management team includes the folowing people:
  • Mr. David Alan Dodd, Chairman, CEO & Pres (Age 69)
  • Dr. Harriet Latham Robinson, Co-Founder, Chief Scientific Officer Emeritus & Director (Age 81)
  • Mr. Mark W. Reynolds CPA, CPA, CFO & Corp. Sec. (Age 57)
  • Dr. Farshad Guirakhoo, Chief Scientific Officer (Age 66)
  • Mr. Donald G. Hildebrand, Founder, Chairman Emeritus & Consultant (Age 78)

How do I buy shares of Geovax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Geovax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $0.0115.

How big of a company is Geovax Labs?

Geovax Labs has a market capitalization of $30,785.50 and generates $960,000.00 in revenue each year. The biotechnology company earns $-2,560,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Geovax Labs employs 8 workers across the globe.View Additional Information About Geovax Labs.

What is Geovax Labs' official website?

The official website for Geovax Labs is http://www.geovax.com/.

How can I contact Geovax Labs?

Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]


MarketBeat Community Rating for Geovax Labs (OTCMKTS GOVX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about Geovax Labs and other stocks. Vote "Outperform" if you believe GOVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel